Related Experiment Video
Updated: Aug 27, 2026
Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
Ginsenoside Rb1 alleviates isoproterenol- and transverse aortic constriction-induced cardiac fibrosis by suppressing
Bing-Yuan Zhao1, Fan-Kai Chen1, Ding-Zhou Weng1
1Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China; Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China; Academy of Integration of Chinese and Western Medicine, Peking University Health Science Center, Beijing, China; The Key Discipline for Integration of Chinese and Western Basic Medicine (Microcirculation) of the National Administration of Traditional Chinese Medicine, Beijing, China; Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of the People's Republic of China, Beijing, China; Beijing Microvascular Institute of Integration of Chinese and Western Medicine, Beijing, China.
Background:
A major pathological event in heart failure (HF) is cardiac fibrosis induced by pressure overload, and infiltration of monocytes is essential in this scenario. Nevertheless, there are no targeted therapies. Ginsenoside Rb1 (Rb1), a major active component of Panax ginseng, has been proven to have cardioprotective ability, although the exact molecular target is not yet clearly understood.
Methods:
Mouse models of cardiac fibrosis were induced by subcutaneous isoproterenol (ISO) injection or transverse aortic constriction (TAC). Echocardiography, histology, and molecular biology techniques were used to evaluate the effects of Rb1 on cardiac function, hypertrophy, fibrosis, and macrophage infiltration. The direct target of Rb1 was identified through a combined methodology that includes phosphoproteomics, thermal proteome profiling, cellular thermal shift assay, and surface plasmon resonance. The specific role of monocytic Raf1 was further validated using a pharmacological inhibitor (GW5074) and monocyte/macrophage-specific Raf1 knockdown in vivo.
Results:
Rb1 was effective in the prevention of cardiac dysfunction, hypertrophy, and fibrosis in both ISO- and TAC-induced mouse models. These effects were mediated through the inhibition of monocyte recruitment by directly targeting Raf1. Mechanistically, Rb1 interacts with Raf1, inhibits its kinase activity, and consequently suppresses the Raf1-MEK-Erk-Creb signaling, which resulted in decreased CD11b/CD18 expression and inhibited migration of monocytes. Importantly, the anti-fibrotic effects of Rb1 were recapitulated by the Raf1 inhibitor GW5074 and in vivo monocyte/macrophage-specific Raf1 knockdown.
Conclusion:
Our research not only unveils a new immunomodulatory effect of Ginsenoside Rb1 that targets monocytic Raf1 as a key mediator but also notes Raf1 inhibition as a promising therapeutic strategy of HF.
